Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy

Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy

BACKGROUND. This prospective study was undertaken to evaluate patient and treatment characteristics that contribute to hematologic toxicity in older cancer patients. METHODS. A nationwide study of 115 community oncology practices was conducted between 2002 and 2005 with data collected on 976 patient...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer 2007-10, Vol.110 (7), p.1611-1620
Hauptverfasser: Shayne, Michelle, Culakova, Eva, Poniewierski, Marek S., Wolff, Debra, Dale, David C., Crawford, Jeffrey, Lyman, Gary H.
Format: Artikel
Sprache:eng
Schlagworte:
Age Factors
Aged
Aged, 80 and over
aging, colony‐stimulating factor, dose intensity, dose, neutropenic complications
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Biological and medical sciences
Disease-Free Survival
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Granulocyte Colony-Stimulating Factor - therapeutic use
Granulocyte-Macrophage Colony-Stimulating Factor - therapeutic use
Hematologic and hematopoietic diseases
Humans
Logistic Models
Male
Medical sciences
Multivariate Analysis
Neoplasm Staging
Neoplasms - drug therapy
Neoplasms - pathology
Neutropenia - chemically induced
Neutropenia - prevention & control
Other diseases. Hematologic involvement in other diseases
Prospective Studies
Severity of Illness Index
Tumors
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:BACKGROUND. This prospective study was undertaken to evaluate patient and treatment characteristics that contribute to hematologic toxicity in older cancer patients. METHODS. A nationwide study of 115 community oncology practices was conducted between 2002 and 2005 with data collected on 976 patients who had received chemotherapy for common malignancies, including lung cancer, colorectal cancer, breast cancer, ovarian cancer, genitourinary cancer, and lymphoma. Primary outcomes included severe neutropenia (SN) and febrile neutropenia (FN). Secondary outcomes included delivered relative dose intensity (RDI)
ISSN:0008-543X
1097-0142
DOI:10.1002/cncr.22939